Roche and Prothena are advancing Prasinezumab to Phase 3 for Parkinson’s despite mixed Phase 2 results. Click here to read an ...

Prothena Corporation plc (NASDAQ:PRTA) is among the best NASDAQ stocks under $50 to buy. Roche, a partner of Prothena ...

Roche and Prothena are forging ahead to late-stage studies for their investigational Parkinson’s disease antibody ...

Prothena announced partner Roche will advance prasinezumab into Phase III development in early-stage Parkinson’s disease.

Roche has announced that it will be advancing its Prothena-partnered investigational Parkinson’s disease (PD) drug ...

In a report released today, Jay Olson from Oppenheimer maintained a Buy rating on Incyte (INCY – Research Report), with a price target of $82.00. The company’s shares closed l ...

Basel: Roche has announced its decision to proceed with Phase III development of prasinezumab, an investigational ...

The Swiss drugmaker said it was “encouraged” by the signs of effectiveness of the drug, developed by biotech Prothena, showed ...

Roche to advance prasinezumab into phase III development for early-stage Parkinson's disease: Basel Tuesday, June 17, 2025, 09:00 Hrs [IST] Roche announced its decision to proceed ...

Results from Phase IIb PADOVA and longer term follow-up data suggest clinical benefit on top of symptomatic treatment in early-stage Parkinson's diseasePrasinezumab is a potential first-in-class anti- ...